✦ LIBER ✦

Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584

✍ Scribed by Anne L. Thomas; Bruno Morgan; Joachim Drevs; Clemens Unger; Bertram Wiedenmann; Udo Vanhoefer; Dirk Laurent; Margaret Dugan; William P. Steward

Book ID: 114106759
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 279 KB
Volume: 30
Category: Article
ISSN: 0093-7754
DOI: 10.1016/s0093-7754(03)70023-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vascular endothelial growth factor recep

Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity

✍ Aisaku YAMAMOTO; Hideaki WATANABE; Hirohiko SUEKI; Takako NAKANISHI; Hajime YASU 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 749 KB

PTK787/ZK 222584, a small molecule tyros

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

✍ Francis J. Giles; Alan F. List; Michael Carroll; Jorge E. Cortes; Joyce Valickas 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 151 KB

A phase I study of the oral vascular end

A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 143 KB

PTK787/ZK222584, a tyrosine kinase inhib

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

✍ Markus Rudin; Paul M. J. McSheehy; Peter R. Allegrini; Martin Rausch; Diana Baum 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 793 KB

## Abstract Assessment of tumour vascularity may characterize malignancy as well as predict responsiveness to anti‐angiogenic therapy. Non‐invasive measurement of tumour perfusion and blood vessel permeability assessed as the transfer constant, __K__^trans^, can be provided by dynamic contrast‐enha

35 POSTER A Phase I trial of a combinati

35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors

✍ G. Dy; G. Croghan; A. Furth; J. Reid; L. Hanson; M. Roos; A. Tan; A. Adjei 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 134 KB

PTK 787/ZK 222584, a Tyrosine Kinase Inh

PTK 787/ZK 222584, a Tyrosine Kinase Inhibitor of all Known VEGF Receptors, Represses Tumor Growth with High Efficacy

✍ Holger Hess-Stumpp; Martin Haberey; Karl-Heinz Thierauch 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB